Detalhe da pesquisa
1.
The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: a multi-centre observational study.
Diabet Med
; 31(4): 403-11, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24246138
2.
Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*.
Diabetes Obes Metab
; 13(8): 703-10, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21410858
3.
The Association of British Clinical Diabetologists nationwide exenatide and liraglutide audits suggest a low incidence of acute pancreatitis. Response to Robson. Incretins and pancreatitis--what happens next? A personal viewpoint.
Diabet Med
; 30(12): 1510-1, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24117729
4.
Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits.
Diabet Med
; 29(5): 690-2, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21988449
5.
The influence of age and metformin treatment status on reported gastrointestinal side effects with liraglutide treatment in type 2 diabetes.
Diabetes Res Clin Pract
; 109(1): 124-9, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25937541
6.
Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit.
Diabetes Res Clin Pract
; 93(2): e87-e91, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21636161